Balasubramanian R, Rolph R, Morgan C, Hamed H. Genetics of breast cancer: management strategies and risk-reducing surgery. Br J Hosp Med (Lond). 2019;80(12):720–5.

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.

Article  PubMed  Google Scholar 

Bray F, Ferlay J, Laversanne M, Brewster DH, Gombe Mbalawa C, Kohler B, et al. Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration. Int J Cancer. 2015;137(9):2060–71.

Article  CAS  PubMed  Google Scholar 

Collaborative Group on Hormonal Factors in Breast C. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002;360(9328):187–95.

Gage M, Wattendorf D, Henry LR. Translational advances regarding hereditary breast cancer syndromes. J Surg Oncol. 2012;105(5):444–51.

Article  CAS  PubMed  Google Scholar 

Leite AM, Macedo AVS, Jorge AJL, Martins WA. Antiplatelet therapy in breast cancer patients using hormonal therapy: myths, evidence and potentialities - systematic review. Arq Bras Cardiol. 2018;111(2):205–12.

PubMed  PubMed Central  Google Scholar 

Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255–69.

Article  PubMed  PubMed Central  Google Scholar 

Jahanzeb M. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer. 2008;8(4):324–33.

Article  CAS  PubMed  Google Scholar 

Hickey BE, Lehman M. Partial breast irradiation versus whole breast radiotherapy for early breast cancer. Cochrane Database Syst Rev. 2021;8(8):CD007077.

Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci USA. 2008;105(26):9053–8.

Article  PubMed  PubMed Central  Google Scholar 

Chalumeau C, Carton M, Eeckhoutte A, Ballet S, Vincent-Salomon A, Vuagnat P, et al. Oral etoposide and trastuzumab use for HER2-positive metastatic breast cancer: a retrospective study from the institut curie hospitals. Cancers (Basel). 2022;14(9).

Mano MS, Rosa DD, De Azambuja E, Ismael GF, Durbecq V. The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours. Cancer Treat Rev. 2007;33(1):64–77.

Article  CAS  PubMed  Google Scholar 

de Lucio B, Manuel V, Barrera-Rodriguez R. Characterization of human NSCLC cell line with innate etoposide-resistance mediated by cytoplasmic localization of topoisomerase II alpha. Cancer Sci. 2005;96(11):774–83.

Article  PubMed  Google Scholar 

Cohen EN, Jayachandran G, Moore RG, Cristofanilli M, Lang JE, Khoury JD, et al. A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix((R)) PC1 System. Cancers (Basel). 2022;14(21).

Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339(6119):580–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fina E. Signatures of Breast Cancer Progression in the Blood: What Could Be Learned from Circulating Tumor Cell Transcriptomes. Cancers (Basel). 2022;14(22).

Bartkowiak K, Mossahebi Mohammadi P, Gartner S, Kwiatkowski M, Andreas A, Geffken M, et al. Detection and Isolation of Circulating Tumor Cells from Breast Cancer Patients Using CUB Domain-Containing Protein 1. J Proteome Res. 2023.

Klusa D, Lohaus F, Franken A, Baumbach M, Cojoc M, Dowling P, et al. Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy. Int J Cancer. 2023.

Jimenez-Fonseca P, Sastre J, Garcia-Alfonso P, Gomez-Espana MA, Salud A, Gil S, et al. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNU-1 and Phase II VISNU-2 Randomized Trials. Clin Colorectal Cancer. 2023.

Ricordel C, Chaillot L, Vlachavas EI, Logotheti M, Jouannic A, Desvallees T, et al. Genomic characteristics and clinical significance of CD56+ circulating tumor cells in small cell lung cancer. Sci Rep. 2023;13(1):3626.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90.

Article  CAS  PubMed  Google Scholar 

Obermayr E, Koppensteiner N, Heinzl N, Schuster E, Holzer B, Fabikan H, et al. Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer. J Pers Med. 2021;11(11).

Yang J, Ma J, Jin Y, Cheng S, Huang S, Zhang N, et al. Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial-mesenchymal transition. Sci Rep. 2021;11(1):6540.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao T, Mao J, Huang J, Luo F, Lin L, Lian Y, et al. Prognostic significance of circulating tumor cell measurement in the peripheral blood of patients with nasopharyngeal carcinoma. Clinics (Sao Paulo). 2023;78: 100179.

Article  PubMed  Google Scholar 

Wang HT, Bai LY, Wang YT, Lin HJ, Yang HR, Hsueh PR, et al. Circulating tumor cells positivity provides an early detection of recurrence of pancreatic cancer. J Formos Med Assoc. 2023.

MB A, SB E, FL G. AJCC Cancer Staging Manual. 8th ed. Springer. 2017.

Li J, Liao Y, Ran Y, Wang G, Wu W, Qiu Y, et al. Evaluation of sensitivity and specificity of CanPatrol technology for detection of circulating tumor cells in patients with non-small cell lung cancer. BMC Pulm Med. 2020;20(1):274.

Article  PubMed  PubMed Central  Google Scholar 

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology/college of american pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36(20):2105–22.

Article  CAS  PubMed  Google Scholar 

Joseph C, Papadaki A, Althobiti M, Alsaleem M, Aleskandarany MA, Rakha EA. Breast cancer intratumour heterogeneity: current status and clinical implications. Histopathology. 2018;73(5):717–31.

Article  PubMed  Google Scholar 

Li Y, Jiang X, Zhong M, Yu B, Yuan H. Whole genome sequencing of single-circulating tumor cell ameliorates unraveling breast cancer heterogeneity. Breast Cancer (Dove Med Press). 2022;14:505–13.

CAS  PubMed  PubMed Central  Google Scholar 

Maurer M, Schott D, Pizon M, Drozdz S, Wendt T, Wittig A, et al. Increased circulating epithelial tumor cells (CETC/CTC) over the Course of Adjuvant Radiotherapy Is a Predictor of Less Favorable Outcome in Patients with Early-Stage Breast Cancer. Curr Oncol. 2022;30(1):261–73.

Article  PubMed  PubMed Central  Google Scholar 

Dong J, Zhu D, Tang X, Qiu X, Lu D, Li B, et al. Detection of circulating tumor cell molecular subtype in pulmonary vein predicting prognosis of stage I-III non-small cell lung cancer patients. Front Oncol. 2019;9:1139.

Article  PubMed  PubMed Central  Google Scholar 

Fountzilas G, Valavanis C, Kotoula V, Eleftheraki AG, Kalogeras KT, Tzaida O, et al. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. J Transl Med. 2012;10:10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huijsmans CJ, van den Brule AJ, Rigter H, Poodt J, van der Linden JC, Savelkoul PH, et al. Allelic imbalance at the HER2/TOP2A locus in breast cancer. Diagn Pathol. 2015;10:56.

Article  PubMed  PubMed Central  Google Scholar 

Yang Z, Liu Y, Shi C, Zhang Y, Lv R, Zhang R, et al. Suppression of PTEN/AKT signaling decreases the expression of TUBB3 and TOP2A with subsequent inhibition of cell growth and induction of apoptosis in human breast cancer MCF-7 cells via ATP and caspase-3 signaling pathways. Oncol Rep. 2017;37(2):1011–9.

Article  CAS  PubMed  Google Scholar 

Menendez JA, Vellon L, Lupu R. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br 3 breast cancer cells: in vitro evidence for a “functional amplicon” involving FAS, Her-2/neu and TOP2A genes. Int J Mol Med. 2006;18(6):1081–7.

CAS  PubMed  Google Scholar 

Bartsch R, Bergen E. ASCO 2018: highlights in HER2-positive metastatic breast cancer. Memo. 2018;11(4):280–3.

Article  PubMed  PubMed Central  Google Scholar 

Papadaki MA, Stoupis G, Theodoropoulos PA, Mavroudis D, Georgoulias V, Agelaki S. Circulating tumor cells with stemness and epithelial-to-mesenchymal transition features are chemoresistant and predictive of poor outcome in metastatic breast cancer. Mol Cancer Ther. 2019;18(2):437–47.

Article  CAS  PubMed  Google Scholar